FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022384780> ?p ?o ?g. }

• W2022384780 endingPage "1799" @default.
• W2022384780 startingPage "1798" @default.
• W2022384780 abstract "To the Editor: The emergence of widespread resistance to chloroquine and sulfadoxine-pyrimethamine in Africa has caused a sharp rise in deaths from malaria. The World Health Organization therefore urgently recommends replacement of these drugs, particularly with combinations that include an artemisinin compound (AC) (1). In 2006, although >40 countries have adopted artemisinin-based combination therapies as their first-line treatment for malaria, only a few of these countries actually use these combination therapies because of limiting factors such as high cost (2). When used as monotherapy, ACs are associated with high rates of recrudescence, possibly because of their short elimination half-lives (3). Most artemisinin-based combination therapies contain, in addition to ACs, a partner drug against which resistance has already developed (e.g., mefloquine, amodiaquine, lumefantrine); reports of relatively low efficacy of the combination artesunate-amodiaquine have been recently published (4). In 2005, Jambou et al. claimed to have found the first cases of in vitro Plasmodium falciparum resistance to ACs (5).We assessed the in vitro susceptibility to dihydroartemisinin (dhART), the biologically active metabolite of artemisinin derivatives, of P. falciparum isolates from travelers returning to France from various African countries during 2004–2006. In addition, we searched for polymorphism in the P. falciparum adenosine triphosphatase-6 (PfATPase6) gene, which was reported to be associated with in vitro artemether resistance (5). We also studied polymorphism (a 3-bp indel) in the gene of the ABC transporter G7, which was reported in 2005 to be associated with in vitro response to artesunate (6).Determination of in vitro dhART susceptibility by using the isotopic semimicrotest method (7) was successful for 397 isolates. The most represented countries were Cameroon (17%), Cote d'Ivoire(14.5%), Mali (12%), Comoros Islands (8.5%), and Senegal (6.5%). Patients were 10 nmol/L for 6. Thus, some isolates showed a diminished susceptibility to dhART, but only 1 isolate had an IC50 >30 nmol/L (31.8 nmol/L).DNA sequencing of 900-bp and 240-bp PCR products, including the 769 and the 243/263 PfATPase6 codons, respectively, was performed in a subsample of 154 isolates. All isolates had the S769 wild codon except 1 susceptible isolate (IC50 = 0.83 nmol/L), which had a S769N mutant type codon (Table). We found no polymorphism in codon 263. This position may be scrutinized to monitor anticipated artemisinin resistance, according to a recently published structure-function study (8). Conversely, we found 2 isolates that had IC50 values of 4.2 nmol/L and 6.4 nmol/L and that showed an H243Y mutant type codon. The role of such a polymorphism appears unclear. We found no association between the 3-bp indel in G7 and in vitro dhART susceptibility because mutants were regularly distributed in highly susceptible isolates and in isolates having a diminished susceptibility.TablePolymorphism in PfATPase6 and G7 genes and in vitro susceptibility to dihydroartemisinin of 154 Plasmodium falciparum isolates*For our samples obtained during 2004–2006, the geometric mean IC50 value for dhART was very close to values found in Cameroon during 1997–1998 (mean dhART IC50 = 1.11 nmol/L) (9), in Senegal in 2001 (mean artemether IC50 = 1.3 nmol/L) (5), and in Republic of Congo during 2005–2006 (mean dhART IC50 = 1.02 nmol/L) (10). Ringwald et al. observed a narrower range of IC50s, but their series included only 65 samples (9). Previous comparisons between ACs suggested that dhART is 1.7 times more potent than artemether against P. falciparum (9). Thus, the highest IC50 value for artemether observed by Jambou et al. in Senegal (44.7 nmol/L) (5) is comparable to the highest IC50 value for dhART in our series (31.8 nmol/L). The resistance levels of ACs are still undefined. For artemether, Jambou et al. used a threshold of 30 nmol/L to evaluate the association between the S769N mutation and in vitro susceptibility. The presence of ATPase6 S769N was not associated with diminished in vitro susceptibility in our series. Conversely, the only S769N mutant that we observed was found in a fully susceptible isolate. Thus, we confirmed that polymorphism exists in this gene in positions 769 and 243, but we did not prove an association between these point mutations and resistance to ACs. Similarly, our results did not support the hypothesis of an association between the 3-bp indel in G7 and resistance to ACs.ACs, considered the most important class of antimalarial drugs, merit close surveillance for susceptibility. Continued monitoring of the efficacy of their associated partner drugs also appears to be essential." @default.
• W2022384780 created "2016-06-24" @default.
• W2022384780 creator A5007987175 @default.
• W2022384780 creator A5063959627 @default.
• W2022384780 creator A5070258082 @default.
• W2022384780 creator A5072820333 @default.
• W2022384780 date "2006-01-01" @default.
• W2022384780 modified "2023-09-25" @default.
• W2022384780 title "Resistance to Dihydroartemisinin" @default.
• W2022384780 doi "https://doi.org/10.3201/eid1211.060903" @default.
• W2022384780 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3372362" @default.
• W2022384780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17283645" @default.
• W2022384780 hasPublicationYear "2006" @default.
• W2022384780 type Work @default.
• W2022384780 sameAs 2022384780 @default.
• W2022384780 citedByCount "39" @default.
• W2022384780 countsByYear W20223847802012 @default.
• W2022384780 countsByYear W20223847802013 @default.
• W2022384780 countsByYear W20223847802016 @default.
• W2022384780 countsByYear W20223847802017 @default.
• W2022384780 countsByYear W20223847802020 @default.
• W2022384780 crossrefType "journal-article" @default.
• W2022384780 hasAuthorship W2022384780A5007987175 @default.
• W2022384780 hasAuthorship W2022384780A5063959627 @default.
• W2022384780 hasAuthorship W2022384780A5070258082 @default.
• W2022384780 hasAuthorship W2022384780A5072820333 @default.
• W2022384780 hasBestOaLocation W20223847803 @default.
• W2022384780 hasConcept C114851261 @default.
• W2022384780 hasConcept C18903297 @default.
• W2022384780 hasConcept C203014093 @default.
• W2022384780 hasConcept C2776120307 @default.
• W2022384780 hasConcept C2778048844 @default.
• W2022384780 hasConcept C2778371730 @default.
• W2022384780 hasConcept C2781160685 @default.
• W2022384780 hasConcept C501593827 @default.
• W2022384780 hasConcept C57473165 @default.
• W2022384780 hasConcept C71924100 @default.
• W2022384780 hasConcept C86803240 @default.
• W2022384780 hasConcept C89423630 @default.
• W2022384780 hasConcept C94665300 @default.
• W2022384780 hasConceptScore W2022384780C114851261 @default.
• W2022384780 hasConceptScore W2022384780C18903297 @default.
• W2022384780 hasConceptScore W2022384780C203014093 @default.
• W2022384780 hasConceptScore W2022384780C2776120307 @default.
• W2022384780 hasConceptScore W2022384780C2778048844 @default.
• W2022384780 hasConceptScore W2022384780C2778371730 @default.
• W2022384780 hasConceptScore W2022384780C2781160685 @default.
• W2022384780 hasConceptScore W2022384780C501593827 @default.
• W2022384780 hasConceptScore W2022384780C57473165 @default.
• W2022384780 hasConceptScore W2022384780C71924100 @default.
• W2022384780 hasConceptScore W2022384780C86803240 @default.
• W2022384780 hasConceptScore W2022384780C89423630 @default.
• W2022384780 hasConceptScore W2022384780C94665300 @default.
• W2022384780 hasIssue "11" @default.
• W2022384780 hasLocation W20223847801 @default.
• W2022384780 hasLocation W20223847802 @default.
• W2022384780 hasLocation W20223847803 @default.
• W2022384780 hasLocation W20223847804 @default.
• W2022384780 hasOpenAccess W2022384780 @default.
• W2022384780 hasPrimaryLocation W20223847801 @default.
• W2022384780 hasRelatedWork W167078013 @default.
• W2022384780 hasRelatedWork W1965918912 @default.
• W2022384780 hasRelatedWork W2031224848 @default.
• W2022384780 hasRelatedWork W2034175095 @default.
• W2022384780 hasRelatedWork W2082141826 @default.
• W2022384780 hasRelatedWork W265467801 @default.
• W2022384780 hasRelatedWork W2793028953 @default.
• W2022384780 hasRelatedWork W4366539474 @default.
• W2022384780 hasRelatedWork W2331312648 @default.
• W2022384780 hasRelatedWork W2785882812 @default.
• W2022384780 hasVolume "12" @default.
• W2022384780 isParatext "false" @default.
• W2022384780 isRetracted "false" @default.
• W2022384780 magId "2022384780" @default.
• W2022384780 workType "article" @default.